The Patient Journey – Experience from Symptoms to Diagnosis among Patients with Small Intestinal Neuroendocrine Tumours (SINET) Abstract #2789

Introduction: Patients with SINET often have diffuse symptoms delaying diagnosis. In a patient survey it was observed that 1/3 of NET patients had a time span to diagnosis of > 5 years, with a median of 52 months. Here we assess the patients’ experience during that time period.
Aim(s): To analyse the SINET patients’ experience during their journey from first symptom to diagnosis, objectively assess the time span and identify factors impacting this interval.
Materials and methods: Patients diagnosed with SINET during 2016-17 in western Sweden were involved in semi-structured interviews where data were analysed by clustering in a KJ-analysis. Medical records were analysed to collect time points and visits.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Study Coordinato Kajsa Oberg Holgersson

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2758 Survival According to Therapy Regimen for siNET: Data from 145 Patients from a German Tertiary Referral Centre, Preliminary Results
Introduction: Scarce data exists for therapy regimens other than SSRA and PRRT for siNET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr. Christine Koch
Authors: Bambey C, Koch C, Filmann N, Husmann G, ...
#3078 Gastroenteropancreatic Neuroendocrine Tumor: Experience of an Algerian Centre
Introduction: Gastroenteropancreatic neuroendocrine neoplasms (GEP-NETs) constitute a rare and heterogeneous group of tumors and still constitute a diagnostic and therapeutic challenge.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Dr Mohammed Alaeddine Saidi
Authors: Aris H, Ghomari S, ...
#829 On the Benign Side of Malignancy: How Neuroendocrine Tumors are Experienced by Patients and Their Family Carers
Introduction: Neuroendocrine tumors (NETs) are rare, slow-growing neoplasia with variable clinical presentations. Due to their non-specific symptoms and a lack of diagnostic tools, late diagnosis is common. There is little research relating to NETs as experienced by both patients and family carers.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: ...none of the below
Presenting Author: Susanne Kall
Authors: Kall S, Spichiger E, Stoll H, ...
#849 Patient-Reported Symptom Experiences Following Participation in a Study of Telotristat Etiprate for Patients with Neuroendocrine Tumors and Diarrhea Not Adequately Controlled on Octreotide
Introduction: Telotristat etiprate (LX1606), an oral tryptophan hydroxylase (TPH) inhibitor, was recently evaluated in a dose-escalation (DE) study in patients (pts) with carcinoid tumors and diarrhea not adequately controlled on octreotide.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Others
Presenting Author: Dr. Matthew H Kulke
#1667 A Qualitative Exploration into the Experience of Neuroendocrine Pancreatic Cancer Patients Receiving Molecular Targeted Therapies
Introduction: Despite extensive efficacy date and limited data examining drug related side effects, the patient experience and quality of life data is limited for this patient group
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: Elizabeth Quaglia
Keywords: Sunitinib, everolimus